anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. Clathrate of dehydroepiandrosterone (DHEA) possibly in the form of sulphate, in a matrix of an alpha-, beta- or gamma-cyclodextrin, characterized by containing a cosolubilization agent selected from the group comprising an amino acid, crospovidone, polyethylene glycol 4000, cellulose, carboxymethyl cellulose, starch, tartaric acid, succinic acid, and glutaric acid. 2. Clathrate according to Claim 1, characterized in that said amino acid is selected from the group comprising glycine, lysine, serine and aspartate. 3. Clathrate according to Claim 1, characterized in that the molar ratio between said DHEA and said cyclodextrin is between 3 : 1 and 1 : 10. 4. Clathrate according to Claim 1, characterized in that the molar ratio between said DHEA and said cyclodextrin is 1 : 1. 5. Clathrate according to claim 1, characterized in that the molar ratio between said DHEA and said alpha-cyclodextrin is 1:1. 6. Clathrate according to Claim 1, characterized in that the weight amount of said co-solubilization agent is between 5 and 50%. 7. Clathrate according to Claim 1, characterized in that the weight amount of said co-solubilization agent is 10%. 8. Pharmaceutical compositions comprising a pharmacologically effective amount of a clathrate according to Claim 1, in a mixture with excipient and diluent substances normally used in pharmaceutical techniques. 9. Composition according to Claim 8, characterized in that one part of the composition is formulated so as to enable a fast release of DHEA, and the remaining part is formulated so as to enable a slow release of DHEA. 10. Compositions according to Claim 8, suitable for the treatment of pathological conditions comprising disorders resulting from adrenocortical insufficiency, adrenopausal disorders, hypogonadism and xerophthalmia. 11. Therapeutic method for the treatment of disorders resulting from adrenocortical insufficiency, adrenopausal disorders, hypogonadism and xerophthalmia, comprising the oral administration of a dose of from 12.5 to 50 mg per day of DHEA in the form of clathrate according to Claim 1.
Subjects will exercise during three study visits. During one visit, blood sugar will be controlled using standard insulin pump therapy. The investigators blood glucose control system will manage blood sugar for subjects during the other visits, with exercise announcement with insulin and glucagon delivery modifications during one visit. Treatment order will be randomized. Heart rate and accelerometry data will also be collected during each visit for the purposes of designing an exercise detection system for future studies.

Each subject will be asked to undergo an eligibility screening and to sign a consent form before any study procedures take place. At the screening appointment, after the consent form is signed, blood will be drawn for laboratory tests and a brief physical exam will be performed. An EKG and VO2max test will be completed at screening. Subjects that are enrolled in the study will come in for a sensor insertion visit up to 72 hours before each study visit. Subjects will undergo three 21-hour studies at an OHSU clinic or the OHSU clinical research center. Subjects will arrive at the research center at 8pm. Approximately 2 hours after a low-carbohydrate breakfast on Day 2, subjects will exercise for 45 minutes at 60% of their VO2max determined at screening. Three hours after completion of exercise, subjects will eat lunch. The study will end \~5 hours after lunch. Capillary blood glucose (CBG) will be measured every 2 hours during the day, every 3 hours at night and before and after exercise for studies using the blood glucose control system with subjects blinded to the CBG values. For studies using insulin pump therapy, the subject will sample CBG four times during the day as well as before and after exercise. Study staff will monitor studies remotely using a cloud server. An investigator or nurse practitioner with a specialty in endocrinology or internal medicine will be on site (located within the same complex) at all times.
Two different crossover designs are chosen. Both are randomized, open-label, two-sequence, two periods crossover designs comparing the new niclosamide solution with the marketed chewing tablets. Planned doses are 1600 mg once daily (oral solution), 2000 mg once daily (chewing tablets) and 500 mg three times daily of both dosage forms.
Objective: To analyse the characteristics of micronuclus and chromosomal aberrations and the lens opacity in different working years, ages and work type of radiation workers with lens opacity. Methods: In January 2022, we selected 400 radiation workers with lens opacity who had undergone occupational health examination in Hangzhou Hospital for the Prevention and Treatment of Occupational Disease from March 2014 to December 2021 as research objects. To analyze the differences of micronucleus, chromosome aberration and the lens opacification rates of different length of service, type of work, age radiologic workers. Results: The results showed that radiation the micronucleus abnormality (0.59‰) and chromosome aberration (2.67%) in peripheral blood in workers who served more than 20 years were significantly higher than that of micronucleus abnormality (0.18‰) and chromosome aberration (0.31%) in workers served less than 20 years, the differences were statistically significant (P<0.05). The micronucleus abnormality (0.32‰) and chromosome aberration (0.57%) in the interventionist were higher than oral radiation workers (0.12‰ and 0.19%) and diagnostic radiologist (0.05‰ and 0.12%), the differences were statistically signcficant (χ(2)=23.98, 6.72, P<0.05) . Conclusion: The rates of micronucleus and chromosome aberration of the interventionaist are higher than oral radiation workers and the traditional radiologist. Workers engaged in radiation should improve personal protection and undertake regular occupational health examinations.
Ablation of persistent/permanent Atrial Fibrillation (AF) remains a challenge. There are several strategies to improve the outcomes of persistent/permanent AF ablation. At the Cleveland Clinic one of the commonly used strategies is Direct Current Cardioversion (DCC). Depending on physician preference, patients may be ablated in atrial fibrillation then Direct current cardioverted; or Direct current cardioverted and ablated in sinus rhythm. Neither approach has been shown to be superior. As both approaches are currently being performed based on physician preference, the investigators propose to study and compare both approaches in a randomized fashion for evidence based practice.

The purpose of this study is to compare which standard of care strategy is superior in patients with persistent/permanent Atrial Fibrillation undergoing ablation, direct current cardioversion prior to empirical pulmonary vein isolation; or ablation in atrial fibrillation then direct current cardioversion if the patient remains in atrial fibrillation
1. A method for preparing a medicament from brain tissue of animal embryo comprising cooling initial material, homogenization, extraction of highly-active polypeptides from homogenate, preservation, sterilization, filtration and subsequent stabilization of the obtained polypeptide solution, characterized in that prior to homogenization the initial material is cooled to a temperature of -5 to -10 degree C and maintained during 24 hours at +10 degree C, the homogenate is extracted in two steps, wherein 9% solution of potassium sulfate is used as extracting solution. 2. The method of claim 1, characterized in that after the filtration the polypeptide solution is subjected to stabilization by 0.07% alcohol solution of p-oxybenzoic acid methyl ether. 3. A pharmaceutical composition with neuro-protective activity comprising an active substance and a stabilizer, characterized in that the composition comprises a therapeutically effective amount of the medicament as the active substance obtained by the method of claim 1 and the stabilizer, wherein 100 ml of the composition comprises: p-oxybenzoic acid methyl ether 0.07g. active substance up to 100 ml pH 6.5 - 7.5
The trial will enrol virologically suppressed HIV infected volunteers who are stable on ATV/r and 2 NRTI containing ART following stringent screening to rule out evidence of renal, hepatic or gastrointestinal dysfunction which may affect the PK evaluation. A steady-state PK (PK1) sample collection shall be done on day 7 (+/-3) after enrolment. RIF will be added at standard dose (600 mg once daily) with a further PK evaluation 14 days later (PK2); due to the potential risk of sub therapeutic PI concentrations and emergence of HIV drug resistant strains, these individuals will be given DTG 50 mg twice daily for the duration of the dose-escalation study. ATV/r dose will be increased in a single step to the total modelled dose (PK3), given as twice daily doses. Once at maximum ATV/r dose, RIF will be increased to 1200 mg once a day for a further seven days (PK4). RIF will then be stopped, ATV/r stepped down to 300/100mg once a day and DTG continued for a further one week.
A composition comprising an extract of Scrophularia buergeriana Miq. and an extract of poria cocos wolf is provided to prevent or improve skin dryness, atopic dermatitis, cotagious dermatitis or eczema and be usefully used as a cosmetic or a pharmaceutical composition for reinforcing skin barrier function and inducing skin keratinocyte differentiation. A skin external application composition for moisturizing comprises 0.0001-30 wt.% of an extract of Scrophularia buergeriana Miq. as an effective ingredient. The composition further comprises an extract of Poria cocos wolf. In the composition, the extract of the Scrophularia buergeriana Miq. is prepared by extracting or fractionating the Scrophularia buergeriana Miq. with a solvent selected from the group consisting of water, ethanol, methanol, hexane, ethylacetate and butanol. Further, the skin external application composition is used as ointment, gel, cream or powder.
The invention discloses an oxindole spiro dibenzo [ b, f ] oxepin structure with biological activity and a synthesis method and application thereof. The present invention provides oxoindole spiro dibenzo [ b, f ] oxocyclooctane structures. The invention provides a synthesis method thereof, which comprises the following steps: the quaternary synthon containing the oxindole skeleton and 1,2-di (bromomethyl) benzene are uniformly mixed in a solvent and react under certain conditions to prepare the oxindole spiro dibenzo [ b, f ] oxooctane compound. The invention provides a pharmaceutical composition. The invention also provides application of the oxindole spiro dibenzo [ b, f ] oxooctane skeleton in preparation of medicaments for treating cancers and the like. The method for efficiently synthesizing the oxindole spiro-dibenzo [ b, f ] oxooctane compound provided by the invention realizes the efficient synthesis of the oxindole spiro-dibenzo [ b, f ] oxooctane compound based on the cyclization reaction of [4+4] for the first time.
BACKGROUND: Little is known about how well trial participants with chronic kidney disease (CKD) represent real-world adults with CKD. We assessed the population representativeness of clinical trials supporting the 2021 Kidney Disease: Improving Global Outcomes blood pressure (BP) guidelines in real-world adults with CKD.
METHODS AND RESULTS: Using a cross-sectional analysis, we identified patients with CKD who met the guideline definition of hypertension based on use of antihypertensive medications or sustained systolic BP ≥120 mm Hg in 2019 in the Veterans Affairs and Kaiser Permanente of Southern California. We applied the eligibility criteria from 3 BP target trials, SPRINT (Systolic Pressure Intervention Trial), ACCORD (Action to Control Cardiovascular Risk in Diabetes), and AASK (African American Study of Kidney Disease), to estimate the proportion of adults with a systolic BP above the guideline-recommended target and the proportion who met eligibility criteria for ≥1 trial. We identified 503 480 adults in the Veterans Affairs and 73 412 adults in Kaiser Permanente of Southern California with CKD and hypertension in 2019. We estimated 79.7% in the Veterans Affairs and 87.3% in the Kaiser Permanente of Southern California populations had a systolic BP ≥120 mm Hg; only 23.8% [23.7%-24.0%] in the Veterans Affairs and 20.8% [20.5%-21.1%] in Kaiser Permanente of Southern California were trial-eligible. Among trial-ineligible patients, >50% met >1 exclusion criteria.
CONCLUSIONS: Major BP target trials were representative of fewer than 1 in 4 real-world adults with CKD and hypertension. A large proportion of adults who are at risk for cardiovascular morbidity from hypertension and susceptible to adverse treatment effects lack relevant treatment information.
The control group received conventional physiotherapy for 60 minutes per session. Conventional physiotherapy consisted of 30 minutes of therapist-assisted gait and balance training and 30 minutes of strengthening exercises. The both group patients received five training sessions per week for 8 weeks (a total of 40 sessions).
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and fibromyalgia (FM) are chronic syndromes of unknown etiology, accompanied by numerous symptoms affecting neurological and physical conditions. Despite frequent revisions of the diagnostic criteria, clinical practice guidelines are often outdated, leading to underdiagnosis and ineffective treatment. Our aim was to identify microRNA (miRNA) biomarkers implicated in pathological mechanisms underlying these diseases. A comprehensive literature review using publicly accessible databases was conducted. Interesting miRNAs were extracted from relevant publications on ME/CFS and/or FM, and were then linked to pathophysiological processes possibly manifesting these chronic diseases. Dysregulated miRNAs in ME/CFS and FM may serve as promising biomarkers for these diseases. Key identified miRNAs, such as miR-29c, miR-99b, miR-128, miR-374b, and miR-766, were frequently mentioned for their roles in immune response, mitochondrial dysfunction, oxidative stress, and central sensitization, while miR-23a, miR-103, miR-152, and miR-320 were implicated in multiple crucial pathological processes for FM and/or ME/CFS. In summary, both ME/CFS and FM seem to share many dysregulated biological or molecular processes, which may contribute to their commonly shared symptoms. This miRNA-based approach offers new angles for discovering molecular markers urgently needed for early diagnosis or therapeutics to tackle the pathology of these medically unexplained chronic diseases.
PURPOSE:To obtain the titled preparation exhibiting excellent slowly releasing effect, by dispersing an active drug in a gel matrix formed by the use of lecithin and encapsulating the obtained liquid in a gelatin capsule. CONSTITUTION:(Hydrogenated) lecithin is dissolved in an oleophilic base (e.g. animal or vegetable food oil) at 60-70 deg.C, allowed to cool, added with a hydrophilic base (e.g. polyethylene glycol, polyhydric alcohol or sugars) and thoroughly stirred to obtain a gelled product. An active drug is suspended in the gel and the suspension is filled in a gelatin capsule by conventional method to obtain the objective soft capsule preparation. As an alternative method, the active drug is dissolved in the base beforehand and a gel is formed from the solution according to the above steps.
40 patients from American Society of Anesthesiologist (ASA) I- II class, being smokers for at least 10 years or non-smokers, who will undergo elective surgery were included in this randomized prospective study. Patients underwent routine monitoring and neuromuscular monitoring. Propofol 2 mg/kg and intravenous fentanyl 1 mcg/kg were applied at induction. After the loss of eyelash reflex, intravenous rocuronium 0,6 mg/kg was administered. The patient was intubated at a Train of Four count of 2. Anesthesia was continued with 50% O2 + 50% air and sevoflurane 2 % . Rocuronium 0,15 mg/kg was administered when TOF (Train of Four) counter reached 2 during the operation. Sugammadex 2 mg/kg was administered at the end of the operation. The time to reach Train of Four values of 0,7-0,8-0,9 were recorded.
NEW MATERIAL:A 5-fluorothiouracil of formula I (Y is F, Cl, Br, I). EXAMPLE:The compound of formula II. USE:An intermediate of 5-fluorouracils which have antitumor activity. Additionally, some of them can be expected to have antibacterial activity. PREPARATION:3-Halogeno-2,2,3-trifluorooxetane or 2-halogeno-2,3,3- trifluorooxetane of formula II or III (X is F, Cl, Br, I) is allowed to react with thiourea to give the compound of formula I. The compounds of formula I where Y is F are expectedly used as an antibacterial. Further, the compound of formula I is derived to 5-fluorothiouracil by reaction with a base such as sodium alkoxide. The compound can be converted into 5-fluorouracil by refluxing in 2% aqueous ammonia in the presence of Raney nickel for 2-4hr.
In the EG the subjects will perform balance exercises using the OAK system under the supervision of a trained physiotherapist. The treatment will last 3 weeks with daily sessions of 60 minutes, 5 times per week.
Purpura fulminans (PF) is a rare life-threatening infectious disease characterized by the association of a sudden and extensive purpura together with acute circulatory failure. Neisseria meningitidis and Streptococcus pneumoniae are the most frequently involved microorganisms but other species (e.g., Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae...) have also been reported. Despite prompt antibiotics administration and intensive care management, the mortality of PF has been reported to be as high as 50% in previous adult series. Additionally, patients surviving to the early phase of PF are exposed to a high risk of serious sequelae related to extensive skin necrosis and acral symmetrical gangrene, which typically requires limb amputations, a potential source of severe handicap in these previously young and healthy patients. Although the clinical features and outcomes of PF have been well studied in the pediatric setting, the amount of available data for adult PF are scarce, often outdated and mainly limited to patients with meningococcal infections. The current study aims at assessing the short and long-term outcomes of adult patients admitted in the intensive care unit for a purpura fulminans. A large multicenter retrospective cohort will be built in order to assess hospital outcomes (i.e., mortality and amputations). Long-term outcomes, including health-related quality variables, will be prospectively assessed among survivors and compared to septic controls (i.e., patients having septic shock non-related to purpura fulminans).
Pancreatic cancer is the most common medical condition that requires pancreatic resection. Over the last three decades, significant improvements have been made in the conditions and procedures related to pancreatic surgery, resulting in mortality rates lower than 5%. However, it is important to note that the morbidity in pancreatic surgery remains r latively high, with a percentage range of 30-60%. Pre-operative malnutrition is considered to be an independent risk factor for post-operative complications in pancreatic surgery, such as impaired wound healing, higher infection rates, prolonged hospital stay, hospital readmission, poor prognosis, and increased morbidity and mortality. Regarding the post-operative period, it is crucial to provide the best possible management of gastrointestinal dysfunction and to handle the consequences of alterations in food digestion and nutrient absorption for those undergoing pancreatic surgery. The European Society for Clinical Nutrition and Metabolism (ESPEN) suggests that early oral feeding should be the preferred way to initiate nourishing surgical patients as it is associated with lower rates of complications. However, there is ongoing debate about the optimal post-operative feeding approach. Several studies have shown that enteral nutrition is associated with a shorter time to recovery, superior clinical outcomes and biomarkers. On the other hand, recent data suggest that nutritional goals are better achieved with parenteral feeding, either exclusively or as a supplement. The current review highlights recommendations from existing evidence, including nutritional screening and assessment and pre/post-operative nutrition support fundamentals to improve patient outcomes. Key areas for improvement and opportunities to enhance guideline implementation are also highlighted.
PROBLEM TO BE SOLVED: To obtain an extract of pancreas having specific properties and actions on prevention of fatty stool and diarrhea of newborn, especially low-weight newborn, elderly person reduced in function of internal organ, patient of internal organ, etc., by treating the supernatant liquid of a homogenized substance of pancreas with an acid. SOLUTION: The supernatant liquid of a homogenized substance of pancreas is treated with an acid or a buffer solution and allowed to stand at pH4-5 for a moment to give the objective extract of pancreas having the following properties. (A) The extract has lipase activity and raises its activity by the presence of bile acid. (B) The extract has esterase activity and raises its activity by the presence of bile acid. (C) The lipase activity and the esterase activity are stable at pH <9 and the activities are lowered at pH >=9. (D) The extract contains a protein having 10,000-100,000 molecular weight. (E) The extract comprises 60-70g protein based on 100g of the extract (dried substance). (F) The extract contains 10-15g of glucide based on 100g of the extract (dried substance).
PURPOSE: Postoperative pain management has always been a significant challenge for both hospital staff and surgical patients. Determination of pain management outcomes among surgically treated patients may help develop pain management strategies, improve health services that would yield better outcomes, and increase patient satisfaction. This study aimed to assess the outcomes of pain management among postoperative patients.
DESIGN: The study was a descriptive cross-sectional study.
METHODS: The research was performed on postoperative patients at two university hospitals in North Cyprus from July to September 2019. The study sample consisted of 90 patients from both hospitals. The Turkish Version of the revised American Pain Society Patient Outcome Questionnaire (APS-POQ-R-TR) was used for data collection. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist was used to report the present study.
FINDINGS: This study showed that the overall mean for pain severity and the worst pain experienced by patients after 24 hours was slightly higher than medium. Examination of interference of the pain with functions demonstrated that patients experienced problems with physical activities and sleeping. The most experienced side effects were nausea and drowsiness, and the most common emotions were anxiety and helplessness during the postsurgery period. The satisfaction rate of the patients with postoperative pain management was relatively high.
CONCLUSIONS: A holistic approach with evidence-based practices is crucial for adequate postoperative pain management. The recommendations include the development of individual pain outcome strategies to improve overall satisfaction with pain management among postoperative patients.